NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it submitted public comments to the Centers for Medicare and Medicaid Services (CMS) regarding its Proposed Rule for the Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System for 2014. NxStage's comments urge for CMS to correct the current insufficient and inequitable payments for home hemodialysis (HHD) training—making this life-changing modality more accessible to Medicare patients suffering from ESRD.
The Company calls for these changes based upon:
- Clinical data supporting superior patient outcomes with HHD, including more frequent HHD, vs. conventional in-center dialysis;
- Third-party surveys showing that nephrologists and other healthcare professionals would choose HHD most often for themselves if faced with ESRD, contrasting sharply with the small percentage of beneficiaries with access to HHD today;
- A Congressional mandate for CMS to develop policy that encourages more patients to be rehabilitated and treated in the home setting; and,
- Reliable analysis of CMS cost data showing that actual costs incurred per HHD training session ($251-261) are substantially in excess of the current add-on payment ($33.44 per session) for the required training services.
"Today's add-on payment of $33.44 per training session (intended to represent 1 hour of nursing time) is simply too low and does not adequately represent the time and effort required to ensure safe, quality care at home," said Joe Turk, President, NxStage Medical, Inc. "Given the clear and compelling benefits of home hemodialysis and the decades-old Congressional intent to encourage home dialysis and rehabilitation, it is essential that CMS update its policies for training payment to ensure beneficiary access to this modality. It is a disservice to patients to allow this situation to remain unresolved."
A copy of the Company's submission can be found athttp://www.nxstage.com/ourcompany/blog/comments-are-in